eligibility_summary
Eligibility: Adults 18–75 with histologic/cytologic PDAC or IPMN carcinoma after ≥1 prior systemic therapy failure, ECOG 0–2, ≥3‑month life expectancy, measurable disease (RECIST 1.1), adequate organ/bone marrow, prior toxicity ≤Grade 1, contraception if childbearing, consent/compliance. Exclusions: pregnancy/lactation, active infections (HIV, syphilis, HBV, HCV RNA+, EBV/CMV DNA+, TB, COVID), other cancers ≤5 yrs (except BCC, cervical CIS), any condition precluding study.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Interventions and mechanisms: The study tests second-line systemic chemotherapy followed sequentially by NKG2D CAR-NK cell infusions (biological, genetically engineered cell therapy). Chemotherapy (cytotoxic agents) provides tumor debulking and transient lymphodepletion/immunomodulation to enhance adoptive cell therapy. NKG2D CAR-NK cells are NK cells engineered with a chimeric receptor using the NKG2D ectodomain to recognize stress-induced ligands on tumor cells, triggering NK activation, degranulation (perforin/granzyme), cytokine release, and death receptor–mediated apoptosis. Schedule: two IV CAR-NK infusions on days 2–3 after each chemotherapy cycle stops, with dose escalation. Targets (cells/pathways): Tumor cells expressing NKG2D ligands (MICA, MICB, ULBP1–6), NK-cell NKG2D signaling pathway, innate cytotoxic pathways (perforin/granzyme, TRAIL/Fas). Population: unresectable pancreatic ductal adenocarcinoma/IPMN carcinoma after ≥1 prior therapy.